<p>Carfilzomib for relapsed and refractory multiple myeloma</p>
نویسندگان
چکیده
منابع مشابه
Relapsed and RefRactoRy Multiple MyeloMa
• Objective: To review the management considerations in patients with relapsed and refractory multiple
متن کاملTreatment of relapsed and refractory multiple myeloma.
The definition of relapsed and refractory myeloma was straightforward when melphalan-prednisone constituted the mainstay of treatment and high-dose therapy with transplantation was rarely used in myeloma. However, several advances have occurred in the treatment of myeloma over the past decade. Most notably, high-dose therapy and transplantation have become broadly applicable, thalidomide has be...
متن کاملNew hope for relapsed and refractory multiple myeloma.
Myeloma remains an incurable neoplasm despite the development of novel classes of drugs that have greatly prolonged survival of patients over the past 10 years. Patients with advanced refractory or relapsed and refractory myeloma who do not benefi t from these newly developed proteasome inhibitors or immuno modu latory drugs have a median overall survival of only 9 months; this period is an imp...
متن کاملTreatment options for relapsed and refractory multiple myeloma.
Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these trea...
متن کاملElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamet...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Management and Research
سال: 2019
ISSN: 1179-1322
DOI: 10.2147/cmar.s150653